Drug Approval | June 17, 2025
USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
The company received one observation in the Form-483
The company received one observation in the Form-483
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Ranks among the top 15% companies globally
The company received 1 (One) observation in the Form-483
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
25 women students to receive internship, training, and mentorship in Life Sciences segment
Subscribe To Our Newsletter & Stay Updated
